Four Firms Vie For Medicare 2014 New-Tech Add-On Payments
CMS held its annual new-technology Town Hall February 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.
You may also be interested in...
Recent approvals and launches include Cook’s Zilver PTX drug-eluting stent for peripheral arterial disease, Medtronic’s Valiant Captivia stent graft system and Cordis’ S.M.A.R.T. Control vascular stent.
Second Sight Medical Products gains FDA panel endorsement for humanitarian device exemption approval of Argus II, which would be the first artificial retina available to restore vision to the blind.
The firm’s specialized endovascular abdominal aortic aneurysm product was the only device newly awarded a new-technology add-on payment for fiscal 2013, and was moved to a higher-paying procedure category than CMS had previously proposed.